AstraZeneca (LON:AZN) Earns “Buy” Rating from Shore Capital

Shore Capital reissued their buy rating on shares of AstraZeneca (LON:AZN) in a research report report published on Tuesday morning, Marketbeat Ratings reports.

Several other brokerages have also issued reports on AZN. Barclays reiterated an overweight rating and set a £125 ($158.87) price target on shares of AstraZeneca in a report on Monday, April 8th. Jefferies Financial Group reiterated a hold rating and set a £110 ($139.81) price target on shares of AstraZeneca in a report on Friday, February 16th. BMO Capital Markets reiterated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Berenberg Bank lifted their price target on AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the company a buy rating in a report on Friday, May 3rd. Finally, UBS Group reduced their price target on AstraZeneca from £107 ($135.99) to GBX 9,900 ($125.83) and set a sell rating for the company in a report on Monday, February 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of Moderate Buy and a consensus target price of £118 ($149.97).

AstraZeneca Trading Down 0.5 %

LON:AZN opened at £123.44 ($156.89) on Tuesday. The company has a debt-to-equity ratio of 92.51, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a fifty-two week low of GBX 9,461 ($120.25) and a fifty-two week high of £124.88 ($158.72). The stock’s 50-day moving average is £113.29 and its two-hundred day moving average is £106.68. The stock has a market cap of £191.33 billion, a PE ratio of 3,876.25, a price-to-earnings-growth ratio of 0.95 and a beta of 0.16.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.